Merck has detailed the R&D and manufacturing facilities it will close, following the Schering-Plough acquisition - and its Irish facilities appear to emerged unscathed from the shake-up. That's a major achievement for the local management(s) here. Research facilities in the US, Canada, Denmark, Germany and Scotland are affected; so too are manufacturing sites in Italy, Portugal, Mexico, Brazil, Singapore and the US.